Monte Rosa Therapeutics, Inc. (GLUE)

Monte Rosa Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	104.62	132.68	55.87	346.07	42.86	9.25
Short-Term Investments	93.14	104.31	207.91	0	0	0
Cash & Cash Equivalents	197.76	236.99	263.79	346.07	42.86	9.25
Cash Growth	-15.01%	-10.16%	-23.78%	707.39%	363.63%	-
Receivables	0.6	0.51	7.66	0	0	0
Other Current Assets	0.68	-1.29	4.44	2.6	0.73	0.51
Total Current Assets	199.04	236.21	275.89	348.67	43.59	9.76
Property, Plant & Equipment	62.46	62.61	61.91	12.33	4.62	1.34
Long-Term Investments	0	0	4.32	5.34	0	0
Other Long-Term Assets	5.25	4.93	0.28	0	1.16	0
Total Long-Term Assets	67.71	67.54	66.5	17.66	5.79	1.34
Total Assets	266.75	303.76	342.39	366.33	49.38	11.09
Accounts Payable	6.83	11.15	7.86	6.56	7.07	3.2
Deferred Revenue	48.94	50	0	0	0	0
Current Debt	3.35	3.16	3.13	0	0	0.75
Other Current Liabilities	-17.82	-17.72	14.58	10.08	22.21	0.35
Total Current Liabilities	41.29	46.59	25.57	16.64	29.28	4.29
Long-Term Debt	41.84	42.88	43.87	0	0	0
Other Long-Term Liabilities	31.1	35.04	1.53	2.18	1.07	0
Total Long-Term Liabilities	72.93	77.91	45.41	2.18	1.07	0
Total Liabilities	114.23	124.51	70.98	18.81	30.34	4.29
Total Debt	45.18	46.04	47	0	0	0.75
Debt Growth	-2.13%	-2.05%	-	-	-	-
Retained Earnings	-397.86	-365.89	-230.54	-122.04	-48.08	-12.2
Comprehensive Income	-2.69	-2.72	-1.75	-2.02	-1.06	0
Shareholders' Equity	152.52	179.25	271.41	347.52	-48.73	-12.15
Net Cash / Debt	152.57	190.95	216.79	346.07	42.86	8.5
Net Cash / Debt Growth	-18.20%	-11.92%	-37.36%	707.39%	404.57%	-
Net Cash Per Share	2.54	3.72	4.59	13.84	28.26	1.70
Working Capital	157.74	189.62	250.32	332.03	14.32	5.47
Book Value Per Share	2.54	3.49	5.75	13.90	-32.12	-2.43

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).